Show simple item record

dc.contributor.authorKhan, K
dc.contributor.authorCunningham, D
dc.contributor.authorChau, I
dc.date.accessioned2017-07-26T14:24:30Z
dc.date.issued2017-01
dc.identifier.citationCurrent drug targets, 2017, 18 (1), pp. 56 - 71
dc.identifier.issn1389-4501
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/744
dc.identifier.eissn1873-5592
dc.identifier.doi10.2174/1389450116666150325231555
dc.description.abstractColorectal cancer (CRC) is one of the commonest cancers in the world. During the last decade, the development of targeted therapies has given cancer treatment a novel direction in management of metastatic CRC (mCRC) and has enriched the therapeutic armamentarium in the management of this disease. In mCRC, targeting angiogenesis via the vascular endothelial growth factor (VEGF) pathway has been of particular interest based on the favourable survival benefit demonstrated by bevacizumab in clinical trials. More recently, large phase III studies have shown clinical efficacy for the new antiangiogenic agents aflibercept and regorafenib. However, the results of pre-clinical and clinical studies of other anti-angiogenic agents have been disappointing. Furthermore, the benefits from angiogenic inhibitors (AIs) in an unselected patient population are modest. Research into predictive biomarkers is therefore essential, but has, to date, been unsuccessful. Nevertheless, aflibercept and regorafenib have been shown to benefit both bevacizumab naive and refractory patients, suggesting that acquired resistance to AIs can be potentially reversed. This review describes the most recent advances in development of AIs in mCRC with particular focus on aflibercept and regorafenib, the existing challenges for the evaluation of these agents in clinical practice and potential strategies in designing clinical trials that could lead to the discovery of clinically meaningful biomarkers.
dc.formatPrint
dc.format.extent56 - 71
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectPhenylurea Compounds
dc.subjectPyridines
dc.subjectReceptors, Vascular Endothelial Growth Factor
dc.subjectAngiogenesis Inhibitors
dc.subjectVascular Endothelial Growth Factor A
dc.subjectRecombinant Fusion Proteins
dc.subjectTreatment Outcome
dc.subjectSurvival Analysis
dc.subjectSignal Transduction
dc.subjectDrug Resistance, Neoplasm
dc.subjectClinical Trials, Phase III as Topic
dc.subjectMolecular Targeted Therapy
dc.titleTargeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
dc.typeJournal Article
dcterms.dateAccepted2016-03-24
rioxxterms.versionofrecord10.2174/1389450116666150325231555
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent drug targets
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden
dc.contributor.icrauthorChau, Ianen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record